Thousands of miles of planned Asian roads threaten the heart of tiger habitat

Nearly 15,000 miles of new Asian roads will be built in tiger habitat by mid-century, deepening the big cat’s extinction risk and highlighting the need for bold new conservation measures now, according to a new study.

University of Michigan conservation ecologist Neil Carter and his colleagues used a recently developed global roads dataset to calculate the extent and potential impacts of existing and planned road networks across the nearly 450,000-square-mile, 13-country range of the globally endangered tiger.

Fewer than 4,000 tigers remain in the wild. They are found mainly in South Asia and Southeast Asia, regions that will experience accelerating pressure from human development in coming years.

Road construction often exacerbates all three of the main threats to tigers: prey depletion, habitat degradation and poaching.

The U-M-led study showed that existing roads are pervasive throughout tiger habitat, totaling 83,300 miles (134,000 kilometers) in Tiger Conservation Landscapes (TCLs), blocks of habitat across the animal’s range that are considered crucial for recovery of the species. Carter and his co-authors called this finding “a highly troubling warning sign for tiger recovery and ecosystems in Asia.”

The researchers calculated three measures — road density, distance to the nearest road and relative mean species abundance — to characterize how existing road networks influence tiger habitat. They calculated current road densities for all 76 TCLs and summarized those estimates by country and protection status.

In addition, they used published forecasts of global road expansion to calculate the length of new roads that might exist in tiger habitat by 2050, for each of the 13 tiger-range countries.

The study, scheduled for publication April 29 in Science Advances, found that:

  • The 83,300 miles of current road networks within tiger habitat may be decreasing the abundance of tigers and their prey by more than 20%.
  • 43% of the area where tiger breeding occurs and 57% of the area in TCLs are within 5 km (3.1 miles) of a road, a proximity that can negatively impact tigers and their prey.
  • Nearly 15,000 miles of new roads will be built in TCLs by 2050, stimulated through major investment projects such as China’s Belt and Road Initiative.
  • Road densities are, on average, 34% greater in nonprotected portions of TCLs than in strictly protected parts, indicating that road density increases with the relaxation of protection status.
  • Road densities varied widely across tiger-range countries. China’s mean road density in TCLs is nearly eight times greater than Malaysia’s, for example.

“Our analysis demonstrates that, overall, tigers face a ubiquitous and mounting threat from road networks across much of their 13-country range,” said U-M’s Carter, an assistant professor at the School for Environment and Sustainability.

“Tiger habitats have declined by 40% since 2006, underscoring the importance of maintaining roadless areas and resisting road expansion in places where tigers still exist, before it is too late. Given that roads will be a pervasive challenge to tiger recovery in the future, we urge decision makers to make sustainable road development a top priority.”

The world’s remaining tigers are concentrated in a small number of source populations — areas with confirmed current presence of tigers and evidence of breeding — across the animal’s geographic range. Even a small amount of road construction could disproportionately impact tiger recovery by permanently isolating tiger populations, creating tiger “islands,” according to the researchers.

Protecting tigers is a global conservation priority, exemplified by a landmark international initiative, called TX2, with the goal of doubling global tiger numbers between 2010 and 2022. And tigers are considered a conservation flagship species, a popular, charismatic animal that serves as a symbol and rallying point to stimulate conservation awareness and action.

Even so, few studies have assessed the impacts of roads on tigers and their recovery, limiting the impact of tiger conservation planning.

And most previous “road ecology” studies of tigers have focused on localized patterns of wildlife mortality or behavior associated with road design. The new study by Carter and his colleagues, in contrast, estimates road impacts on wildlife at broad scales. It is the first study to include baseline indices on the threat from existing and future roads in tiger habitat.

“This research opens the door to build partnerships at the regional scale to better mitigate existing roads and to develop greener road designs for the next century of infrastructure development,” said study co-author Adam Ford, a wildlife ecologist at the University of British Columbia.

The researchers say their metrics provide tools to support sustainable road development, enabling rapid risk assessment for roads passing through tiger habitat, including roads planned as part of the Belt and Road Initiative.

The BRI is a global development strategy adopted by the Chinese government in 2013 involving infrastructure projects in dozens of countries in Asia, Europe and Africa. The rush to build major new roads throughout the forested regions of South Asia and Southeast Asia, financed through the initiative, could have severe impacts on tigers, according to Carter and his colleagues.

But the BRI could become an important partner in tiger preservation, according to the researchers, by adopting biodiversity conservation as one of its core values. That would set the stage for the BRI to plan and implement a network of protected areas and wildlife corridors to safeguard tigers from road impacts.

Share Button

Remdesivir: Drug has ‘clear cut’ power to fight coronavirus

The data on its effect on symptoms comes from a trial of more than 1,000 patients in the US.

Share Button

Coronavirus ‘as deadly as Ebola in hospital’

Researchers say patients in hospital are as likely to die with Covid-19 as with Ebola.

Share Button

Health24.com | Coronavirus morning update: Why lockdown was eased, 1 million cases in US, and experts speak out on BCG

WHAT’S HAPPENING IN SA

Cases update: 

The latest number of confirmed cases is 4 996.

According to the latest update, 93 deaths have been recorded in the country.

So far, 185 497 tests have been conducted.

READ MORE |All the confirmed cases of coronavirus in SA

Latest news:

The country has 4 996 confirmed Covid-19 cases, with 185 497 tests conducted as of Tuesday, Health Minister Zweli Mkhize announced during a virtual briefing.

In addition, the Department of Health reported three more Covid-19-related deaths, bringing the number to 93.

“We are quite fortunate that we have a low mortality rate of 1.9%, and there are others with underlying conditions who have not passed away,” Mkhize said, adding hypertension and diabetes were among some of the common co-morbidities.

At the briefing, he was joined by his deputy, Joe Phaahla, provincial MECs and experts from the National Institute for Communicable Diseases, where they unpacked the country’s Covid-19 situational analysis and the way forward in a post-lockdown scenario.

Mkhize said President Cyril Ramaphosa’s decision to ease the lockdown was based on scientific calculations.

Ramaphosa announced a risk-adjusted strategy on Thursday to allow for the phased re-opening of the economy.

“We are quite pleased with what has happened, at the point where the president says we need to ease it down, it is based on scientific projections [where] our calculations proved that there was not going to be a further benefit,” Mkhize said.

According to him, the model, which came to that conclusion, found “we need to start managing the lockdown going forward instead of continuing with it as it was”.

Mkhize added factors such as food and income security had come into play for the government when determining how to manage the outbreak and ensuring life was sustainable.

READ MORE | Covid-19 numbers rise to 4 996, with close to 200 000 tests conducted to date

While the country awaits an update from the Department of Basic Education on how it plans to reopen schools post lockdown, unions believe there are outstanding issues that need to be considered before any moves are finalised and revealed to the public.

Basic Education Minister Angie Motshekga and her higher education counterpart, Blade Nzimande, were expected to hold a virtual media briefing on Monday, but it was postponed the day before.

The departments said they needed to align their interventions with those of the National Command Council, which is leading the government’s planning in response to the spread of the coronavirus.

Motshekga, in particular, is under acute pressure to salvage the 2020 academic year.

READ MORE | As govt scrambles to save academic year, safety-first calls grow

While economic activity is expected to be phased in as from this Friday, government is anticipating that the impact of Covid-19 coronavirus will be felt for the foreseeable future.

Mmamoloko Kubayi-Ngubane, chairperson of the economic cluster in the National Coronavirus Command Council, on Tuesday said government’s economic recovery plan would take six to eight months.

Kubayi-Ngubane said the lengthy plan was preferred as government expects the Covid-19 infections to only peak in September.

With this in mind, the tourism minister said she did not expect most industries to be back to full capacity on Friday but expected workers to be reintroduced to the labour force in a phased, risk-adjusted manner that would not undo the work done by the national lockdown.

READ MORE | Government expects lengthy economic recovery period from Covid-19 impact

The Department of Home Affairs will start registering births from 1 May when the country enters a level 4 lockdown, so as to avoid a backlog of birth certificates.

Minister of Home Affairs Aaron Motsoaledi, his deputy, Njabulo Nzuza, and department officials on Tuesday had a virtual meeting with Parliament’s portfolio committee on home affairs and the standing committee on security and justice.

In his presentation, Nzuza said the department decided to render the following three critical services: death registrations, temporary identity certificates and the re-issue of birth certificates.  

From 27 March to 24 April, 2020, the department issued 31 585 death certificates, 4 731 re-issued birth certificates and 9 101 temporary identification certificates.

“The Births and Deaths Act requires that births should be registered within 30 days from date of birth. Ordinarily, any child registered after 30 days is considered as Late Registration of Births (LRB),” reads the presentatio

READ MORE | Home Affairs will register births during level 4 lockdown

WHAT’S HAPPENING IN THE REST OF THE WORLD 

Cases update:

For the latest global data, follow this interactive map from Johns Hopkins University & Medicine.

Late on Tuesday night, positive cases worldwide were just short of 3.1 million, while deaths were more than 216 000.

The United States had the most cases in the world – more than 1 008 000, as well as the most deaths – more than 58 000.

READ MORE | All the confirmed cases worldwide

Latest news:

State and national leaders in the United States signalled an increasing willingness to curtail coronavirus-related lockdowns even as increased testing showed that the number of people infected by the virus surpassed one million for the first time on Tuesday.

More than 57 000 people have died from complications of Covid-19, the disease caused by the coronavirus, public health officials at Johns Hopkins University reported on Tuesday.

The number of reported US cases has doubled in the last 18 days, and now accounts for one-third of all infections in the world. About 30 percent of the cases have occurred in New York state, followed by New Jersey, Massachusetts, California and Pennsylvania.

Despite the grim milestone, US President Donald Trump was at the forefront of calls to kickstart the country’s economy. In a Monday news briefing, he urged some state leaders to “start thinking about school openings, because a lot of people are wanting to have the school openings”.

READ MORE | US struggles to reopen as coronavirus cases hit 1 million mark

China on Tuesday went on the offensive against international criticism over its handling of the coronavirus pandemic, accusing US politicians of “barefaced lies”.

The new virus first emerged in the Chinese city of Wuhan late last year before spreading across the world, and countries including the United States and Australia have called for an investigation into how the disease transformed into a global pandemic.

But Beijing came out swinging on Tuesday in response to foreign criticism, saying the US was attacking China to divert attention from its own handling of the outbreak.

China also defended its ambassador to Australia who has warned that Chinese people could boycott imported goods in retaliation to the demands for a virus inquiry.

READ MORE | China decries ‘barefaced lies’ over its handling of virus

South Asia could face a further public health crisis as children miss routine vaccinations, the UN warned on Tuesday, spurring fears that the fallout from the novel coronavirus pandemic might reverse hard-earned gains in the region.

The United Nations children’s agency Unicef said hundreds of thousands were at risk as lockdowns across South Asia halted immunisation drives and parents refrained from taking their children to doctors to be inoculated.

“While the Covid-19 virus does not appear to make many children seriously ill, the health of hundreds of thousands of children could be impacted by this disruption of regular immunisation services,” said Jean Gough, director of Unicef’s South Asia office.

“This is a very serious threat. Early action is key.”

READ MORE | South Asia faces fresh health crisis as children miss vaccinations

LATEST RESEARCH

Babies in countries with high rates of tuberculosis must have priority access to the Bacille Calmette-Guerin (BCG) vaccine, warn experts.

There has been an increase in demand for the vaccine after a paper was published that speculated it might offer protection against Covid-19.

But a global shortage of BCG, particularly in 2014 and 2017, resulted in a “dramatic increase in the incidence of TB meningitis in young children”, according to the 11 public health and paediatric specialists in a letter published on Tuesday in the International Journal of Tuberculosis and Lung Disease.

Describing BCG as a “scarce resource” because of a lack of production facilities, the authors appeal to the global community to exercise “responsible stewardship” by ensuring that the vaccine goes first to all newborns and unvaccinated children under the age of three where TB is prevalent.

“The use of BCG for an unproven indication is irresponsible and may deplete BCG stocks for young children, for whom it has been proven to be a lifesaving preventive tool against TB-related morbidity and mortality,” state the experts, including Professor Simon Schaaf from the Desmond Tutu TB Centre and University of Stellenbosch’s Paediatrics and Child Health department, Professor Mark Cotton, Director of Stellenbosch’s Children’s Infectious Diseases Clinical Research Unit, and Dr James Seddon from Imperial College in London.

READ MORE | Keep TB vaccine for babies, implore experts

Covid-19, the disease caused by the new coronavirus (SARS-CoV-2), is largely known to cause respiratory complications such as pneumonia, shortness of breath, extreme coughing and even fatal acute respiratory distress syndrome in patients.

As scientists unpack the new coronavirus day by day, we have come to know that it may cause gastrointestinal symptoms and, in some cases, even neurological problems. But what about its effect on the rest of the body – specifically in terms of fertility and the urinary tract? 

New research published in Nature Reviews Urology suggests that there is evidence that Covid-19 has implications for the urogenital tract, something which should be considered when treating Covid-19.

According to the paper, most patients with severe Covid-19 present with pneumonia-related symptoms, but some patients could develop serious urinary tract complications, including acute kidney injury (AKI), which requires continuous renal therapy.

READ MORE | Researchers caution on effects of coronavirus on male fertility

You can’t hug or shake hands these days without risking coronavirus infection, but new research finds that sexual intercourse might be safe.

Researchers analysed semen samples from 34 men in China an average of one month after they were diagnosed with mild to moderate cases of Covid-19, the illness caused by the coronavirus.

Laboratory tests did not detect the coronavirus in any of the semen samples, and there was no evidence of the virus in the men’s testes, according to the study published online recently in the journal Fertility and Sterility.

While this small study suggests that the chances of sexual transmission of the coronavirus are remote, it wasn’t comprehensive enough to fully rule out the possibility, the researchers noted.

READ MORE | You can’t get coronavirus through sex, study suggests

HEALTH TIPS (as recommended by the NICD and WHO)

• Maintain physical distancing – stay at least one metre away from somebody who is coughing or sneezing

• Practise frequent hand-washing, especially after direct contact with ill people or their environment

• Avoid touching your eyes, nose and mouth, as your hands touch many surfaces and could potentially transfer the virus

• Practise respiratory hygiene – cover your mouth with your bent elbow or tissue when you cough or sneeze. Remember to dispose the tissue immediately after use.

READ MORE: Coronavirus 101 

Image credit: Getty Images

Share Button

Health24.com | Lots of drugs are being tested against Covid-19 – but will any work?

Dozens of drugs are being investigated for their value in treating Covid-19, as desperation drives doctors and researchers to look for something that could battle the virus and save lives.

“There are really no FDA-approved medications for the treatment of Covid-19, unfortunately,” said Ashley Barlow, a pharmacy resident with the University of Maryland Medical Center in Baltimore. “We’re doing the best we can to try and ramp up studies, but since we’re doing it in such a quick period of time there are a lot of flaws we have to take into consideration.”

The Covid-19 drugs being tried and tested fall into two general categories, explained Dr Rajesh Gandhi, director of HIV clinical services and education at Massachusetts General Hospital in Boston:

  • Antivirals aimed at limiting the spread of the coronavirus inside the bodies of infected people
  • Immune system medications that limit the damage the body does to itself while fighting off the coronavirus

“There are drugs we believe can help pull people through the natural evolution of this infection and can really make a difference,” Gandhi said. “Right now, the jury is still out on some of these things that have been proposed. That’s why we need to have clinical trials that will provide an answer.”

Remdesivir

Many of the drugs proposed to treat Covid-19 are already approved for other conditions, and can be put into immediate off-label use. That’s not the case with one of the most promising potential therapies, an IV drug called remdesivir, originally developed to treat Ebola and MERS (Middle East respiratory syndrome).

“Remdesivir is not an approved drug, so the only way you can get it is if you are in a clinical trial or through a compassionate use programme,” Gandhi noted.

The drug attacks the genetic code of the Covid-19 coronavirus, hampering its ability to replicate, explained Barlow, lead author of a review of potential coronavirus therapies published recently in the journal Pharmacotherapy.

Early studies in small groups have shown benefit in patients, but doctors are still waiting on results from larger clinical trials to verify those findings, Barlow and Gandhi said.

“I would say in the next month we will probably get an answer on remdesivir,” Gandhi said, adding that even partial benefit would be a good result.

“Even if it doesn’t work 100% of the time, then you have something to build upon,” Gandhi explained. For example, remdesivir could be added to a cocktail of drugs, much in the way that researchers developed an effective therapy for HIV, the virus that causes Aids.

Chloroquine and hydroxychloroquine

These anti-malarial drugs have been touted by President Donald Trump and others as one of the great hopes for Covid-19 treatment.

But these drugs have already laid an egg in several major studies, Barlow said. Clinical trials are ongoing for the two drugs, but researchers aren’t holding out much hope.

“We were looking for a promising drug, and unfortunately hydroxychloroquine ends up being not so promising as we originally thought,” Barlow said.

One nationwide study focusing on its use in US veterans’ hospitals found that 28% of patients treated with hydroxychloroquine died versus 11% of those who didn’t get the drug, according to media reports on Tuesday.

Even before these results, doctors had already started turning away from the drugs, Gandhi said.

“A few weeks ago, when it really started getting intense here in Boston, we were using hydroxychloroquine more than we are now,” Gandhi said. “The waters have remained very muddy. It’s very unclear whether it’s been beneficial, and there are more reports of toxicity.”

Tocilizumab/baricitinib

These immune system-modulating drugs originally were developed to treat rheumatoid arthritis and other inflammatory diseases, Barlow said.

Researchers think they could help Covid-19 patients because the coronavirus appears to trigger an overactive immune response in some people, doing a lot of damage to organs and increasing the risk of death, Barlow and Gandhi said.

“They block one of the alarm bells of the immune system, and try to keep the immune response under control,” Gandhi said, comparing the response to the virus as “when there’s a fire and the fire’s been put out, but the firemen keep trying to put it out.”

This “cytokine storm” can fill lungs with fluid, promote a high fever, or drop blood pressure to dangerously low levels, Barlow said.

Clinical trials for tocilizumab and baricitinib are either underway or in preparation, experts said.

Ribavirin

This broad-spectrum antiviral drug, formerly used to treat hepatitis, is being tried as a Covid-19 therapy and really shouldn’t, Barlow said.

The drug inhibits viral replication by interfering with genetic synthesis, but comes with a host of dangerous side effects.

“It is considered a hazardous drug,” Barlow said. “For us as pharmacists, it’s kind of scary to see people use it because of the significant adverse effects that come with it.”

Ribavirin’s inhaled formulation, for example, can be toxic to foetuses and is not indicated either for pregnant women or their male partners, Barlow and her colleagues said. The drug also can cause anaemia and low blood levels of calcium and magnesium, and has the potential to interact dangerously with immune suppression therapies.

Gandhi said, “I haven’t seen a ton of really exciting data” supporting ribavirin’s use.

Lopinavir/ritonavir/nelfinavir

These drugs were all developed as ways to interfere with the viral replication of HIV, and “in MERS and SARS [severe acute respiratory syndrome] – the other human coronaviruses before Covid-19 – there was some interest in lopinavir/ritonavir,” Gandhi said.

Early randomised trials out of China have not shown any particular benefit, but the World Health Organization and others are still including one or more of the drugs in ongoing Covid-19 clinical trials, Gandhi said.

But, Barlow added, “I think a lot of institutions have stopped using this agent because of the lack of benefit seen.”

Interferon alpha

This drug is one of the older antiviral agents, examined as a means of treating hepatitis and some cancers. It’s based on a protein your own body makes to direct immune response, Gandhi said.

“It’s a natural antiviral that our bodies use, but it’s given as a medication to go beyond what our bodies make,” Gandhi said.

However, there’s little laboratory evidence that interferon alpha is effective in treating either SARS or MERS, Barlow and her colleagues noted.

Nonetheless, ongoing studies are assessing whether interferon alpha used in combination with ribavirin could help treat Covid-19 patients, the experts said.

Interferon alpha generally isn’t used to treat chronic infections like hepatitis because it can cause depression and flu-like symptoms, Gandhi said. However, it could be applied to short-lived infections like Covid-19 if the evidence warrants its use.

“It’s one thing to have flu-like symptoms and depression for a year, it’s another to have it for a week,” Gandhi said.

Nitazoxanide

This drug is approved by the US Food and Drug Administration to treat diarrhoea caused by Giardia parasites, and it has been found to also act against cryptosporidium parasites and some bacteria, Barlow and her colleagues said.

The medication could potentially inhibit the expression of proteins found on the surface of the Covid-19 coronavirus that allow the virus to invade human cells, Barlow said.

Nitazoxanide studies in the lab and with animals have shown that the drug can reduce infections of MERS and other coronaviruses. However, a study published late last year in the journal Clinical Infectious Diseases found the drug did not improve coronavirus patients’ outcomes.

“The history of medicine is just littered with things that looked good in test tubes or in animals, but don’t work well in humans,” Gandhi said of nitazoxanide.

Arbidol/favipiravir/baloxavir

These drugs, approved to treat flu in other nations, are being studied as emerging potential therapies for Covid-19, Barlow and her colleagues said.

Favipiravir is being tested in a clinical trial in the United States, Gandhi said, while other countries are testing the other drugs for their potential in fighting the new coronavirus.

The drugs all work by blocking either the virus’ ability to replicate or to enter human cells.

“That is an interesting drug,” Gandhi said of favipiravir. “I think it’s well worth studying.”

READ | Many approved drugs may hold promise against coronavirus

READ | SA expert cautions on coronavirus treatment

READ | More good news on remdesivir’s power to treat Covid-19

Image credit: Dimitri Karastelev, Unsplash

Share Button

Coronavirus: Thousands of cancer ops at ‘Covid-free’ hubs

A network of centres is established across England to provide essential cancer surgery in safe conditions.

Share Button

Coronavirus: Testing opens for millions more people in England

Staff and residents of care homes, over-65s and people who cannot work at home are now eligible to be tested.

Share Button

Scientists recreate DNA damage caused by toxins from smoking

Researchers from the University of York have recreated how toxins from smoking cause unique patterns of DNA damage. The discovery could help scientists better understand the cause of bladder cancer and the link to smoking.

The causes of bladder cancer remain largely unknown, however smoking is seen as the main risk factor for the disease.

Researchers — led by Dr Simon Baker from the Department of Biology — grew human bladder tissues in the laboratory and exposed them to a common toxin from cigarette smoke. After the tissues were damaged by the smoke toxin, the team analysed all three billion letters of the genetic code (DNA) to find a pattern of changes called a “mutational signature.”

Dr Baker said: “Mutational signatures can be used like fingerprints at a crime scene. When we look at the DNA in a cancer we can see the fingerprints of all the criminals involved in causing the damage that led to cancer.

“The DNA damaging event might be exposure to cigarette smoke or UV from the sun but it might also be an unknown event that causes cancer.”

“Our study found that the smoke toxin left its distinctive fingerprints on the DNA of bladder tissues grown in the laboratory. However, when we looked at the DNA of patients’ bladder cancers the mutational signature, of the smoke toxin, was only responsible for a small amount of the damage.

“So despite smoking being the key risk factor for bladder cancer, direct damage of the DNA by smoke toxins is unlikely to be the main reason for these cancers forming.”

It may be that the smoke toxins accelerate other DNA damaging events and attention is now focussing on a family of enzymes called “APOBEC.”

APOBEC enzymes destroy viruses by mutating their DNA as part of the body’s natural defences against infection, but recent studies suggest they might mistakenly target our own DNA in a number of cancer types. The next stage of the study will be to try and understand how and why APOBEC enzymes become activated in the cells of the bladder.

Story Source:

Materials provided by University of York. Note: Content may be edited for style and length.

Share Button

How hero shrews’ bizarre backbones evolved

At first glance, hero shrews don’t seem super exciting — they’re small grayish-brown mammals, related to moles and hedgehogs, and they look a little bit like chubby, long-nosed rats. But under their fur, they have some of the strangest skeletons in the animal kingdom. Hero shrews have unique interlocking backbones that make their spines insanely strong — the shrews only weigh a quarter of a pound, but there are stories that their backs can support the weight of a full-grown man standing on them. Scientists aren’t sure why these tiny animals developed such crazy backbones, but researchers looking for clues took CT scans of shrew spines to try to get a better sense of how the spines evolved.

“Hero shrews have crazy-looking spines — their vertebrae are squished flat like a pancake, and they have a bunch of extra places where they touch the vertebrae next to them. It makes a really long stiff column along their back, and there aren’t good field reports as to what this structure might be useful for,” says Stephanie Smith, a postdoctoral researcher at the Field Museum and the University of Chicago and the lead author of a new paper in Proceedings of the Royal Society B. “So we wanted to look at those vertebrae and figure out how they might be using them.”

Western scientists first became aware of hero shrews about a hundred years ago, but the Mangbetu people of the Congo Basin have long known about the shrews’ incredible strength. There’s a (maybe apocryphal) story about Mangbetu people showing a team of American and European scientists how a grown man could stand on a hero shrew’s back without hurting it. A second species of hero shrew, with a spine complexity in between that of the original hero shrew and a regular shrew, was described in 2013. But researchers haven’t been able to spot the shrews in the wild putting these backbones to good use — the shrews are hard to find, and they live in areas where political unrest makes research trips nearly impossible.

“There are two species of hero shrew, and they’re both very poorly known. We have specimens of them at the museum, but we can’t see them in action. It’s almost like studying an animal in the fossil record, where we have specimens that tell us about their anatomy, but we can’t bring a live specimen into the lab and observe it,” says Kenneth Angielczyk, a curator of paleontology at the Field Museum and the paper’s senior author.

The authors of the 2013 paper, including the Field’s late head of collections Bill Stanley, posited that the hero shrews’ thick spines might be used as a brace as the animals shifted logs and peeled apart palm stems to get at insects. But no one’s observed them doing that. All we know for sure is that the shrews’ backbones are unique.

“Their spines are arched, and when they contract their muscles to squeeze their vertebrae together, the bones interlock really tightly. When that happens, it becomes one solid block of vertebrae instead of a bunch of bendy pieces,” says Smith.

Without any live shrews to observe, Smith and Angielczyk turned to the bones in the Field Museum’s collections. They took micro-CT scans of the bones of the two known hero shrew species, as well as a “normal” shrew for comparison. These scans revealed minute details of the bones, but more importantly, they also hinted at how the bones were used in life.

“Bones contain a record, to some degree, of the forces that are acting on them during life. There are special cells in the bone that detect when pressure is put on it. They send out signals to reorganize the bone to be better at handling the forces they’re under, so you have bones responding throughout an animal’s life to habitual forces,” explains Smith. “My absolute favorite example of this was a paper where they put sheep in tall shoes, like high heels, and the different angle of pressure changed the inner structure of their leg bones.”

Armed with the knowledge that the inner structure of bone changes depending on the direction of the forces that have acted on the bone, Smith and Angielczyk tried to determine what these shrews had gotten up to. “We found that the two species of hero shrews have really, really thick, dense spongy bone inside their vertebrae. The percentage of bone is high relative to the total volume of the structure compared to other shrews,” Smith says. “That makes the bone a lot sturdier. It’s like how a chair with thick legs and crossbeams connecting those legs is sturdier than a chair with just four spindly legs and no crossbeams.”

“That’s really interesting because it says that these guys can take a lot of force compressing their spine from head to tail. And that’s the main direction that force is applied to the spine in an animal that has four legs,” continues Smith. “It doesn’t necessarily solve the question of what are they doing, but it does give us an indicator that they’re habitually experiencing strong forces in that direction.”

To sum up: hero shrew spines don’t just look tough from the outside, they’re also super dense inside, in a way that indicates that they’re able to withstand pressure from being scrunched up like an inchworm. It doesn’t confirm Stanley’s hypothesis that the shrews scrunch up and then extend their spines to wedge apart palm trunks to get at bugs — only direct observation can do that. But it does indicate that the shrew’s backbones could resist the forces such behavior would generate.

In addition to studying the forces the hero shrews were exposed to in life, Smith also helped quantify the differences between the two known species. The original hero shrew described in 1910 has a more complex spine than the new species from 2013, although the latter has a more complex spine than regular shrews. This suggests the transitional features of the 2013 species (Thor’s hero shrew) can provide information about how the 1910 shrew evolved from a slender-spined ancestor. To help quantify the differences between the shrews’ spines, Smith painstakingly counted all the little nodules and tubercles on the specimens’ vertebrae. “I think the grand total was something like 17,000,” she says. “We found that the Thor’s hero shrew was intermediate on both the inside and the outside. Because of the way that bone reacts to load, that means that it could also be functionally intermediate. But that’s just a hypothesis at this point.”

And if this all seems like a lot of time and effort thinking about shrews at a time when the world has bigger fish to fry, the researchers note that it helps answer bigger questions about the evolution of mammals.

“Small mammals experience the world differently than we do, and we don’t have all that much information about the way that being small affects their interaction with the world,” says Angielczyk. “Part of what we’re interested in is the question of how you can be a small mammal — what do you need to be effective at that and resist forces that are being applied to your body in different functional contexts. It’s something that we don’t know very much about, but it’s important, because we evolved from small mammals. Better knowledge of what it takes to be a small mammal is important for understanding a lot of weird things about mammals in general, including us.”

Smith has no plans to move on from studying shrews anytime soon. “Shrews are really interesting ecologically, and they’re so small they have almost secret powers,” she says. “They’re incredibly diverse, and I think they’re beautiful. They’re dope as hell.”

Share Button

Asteroid 1998 OR2 to safely fly past Earth this week

A large near-Earth asteroid will safely pass by our planet on Wednesday morning, providing astronomers with an exceptional opportunity to study the 1.5-mile-wide (2-kilometer-wide) object in great detail.

The asteroid, called 1998 OR2, will make its closest approach at 5:55 a.m. EDT (2:55 a.m. PDT). While this is known as a “close approach” by astronomers, it’s still very far away: The asteroid will get no closer than about 3.9 million miles (6.3 million kilometers), passing more than 16 times farther away than the Moon.

Asteroid 1998 OR2 was discovered by the Near-Earth Asteroid Tracking program at NASA’s Jet Propulsion Laboratory in July 1998, and for the past two decades astronomers have tracked it. As a result, we understand its orbital trajectory very precisely, and we can say with confidence that this asteroid poses no possibility of impact for at least the next 200 years. Its next close approach to Earth will occur in 2079, when it will pass by closer — only about four times the lunar distance.

Despite this, 1998 OR2 is still categorized as a large “potentially hazardous asteroid” because, over the course of millennia, very slight changes in the asteroid’s orbit may cause it to present more of a hazard to Earth than it does now. This is one of the reasons why tracking this asteroid during its close approach — using telescopes and especially ground-based radar — is important, as observations such as these will enable an even better long-term assessment of the hazard presented by this asteroid.

Close approaches by large asteroids like 1998 OR2 are quite rare. The previous close approach by a large asteroid was made by asteroid Florence in September 2017. That 3-mile-wide (5-kilometer-wide) object zoomed past Earth at 18 lunar distances. On average, we expect asteroids of this size to fly by our planet this close roughly once every five years.

Since they are bigger, asteroids of this size reflect much more light than smaller asteroids and are therefore easier to detect with telescopes. Almost all near-Earth asteroids (about 98%) of the size of 1998 OR2 or larger have already been discovered, tracked and cataloged. It is extremely unlikely there could be an impact over the next century by one of these large asteroids, but efforts to discover all asteroids that could pose an impact hazard to Earth continue.

JPL hosts the Center for Near-Earth Object Studies (CNEOS) for NASA’s Near-Earth Object Observations Program in NASA’s Planetary Defense Coordination Office.

More information about CNEOS, asteroids and near-Earth objects can be found at:

https://cneos.jpl.nasa.gov

For more information about NASA’s Planetary Defense Coordination Office, visit:

https://www.nasa.gov/planetarydefense

For asteroid and comet news and updates, follow @AsteroidWatch on Twitter:

https://twitter.com/AsteroidWatch

Story Source:

Materials provided by NASA/Jet Propulsion Laboratory. Note: Content may be edited for style and length.

Share Button